Your session is about to expire
← Back to Search
Biomarker Analysis for Cervical Cancer Diagnosis
Study Summary
This trialstudies biomarkers to better diagnose cervical lesions, improving treatment plans for abnormal cervical cells.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I was diagnosed with abnormal glandular cells or AIS in the last 6 months and can wait for a specific test.I have HPV and agree to a detailed exam of my uterus and cervix within 6 months after my AGC or AIS diagnosis.I have had a hysterectomy.I have had endometrial, vaginal, or cervical cancer or pre-cancer.I have received or am receiving radiation or chemotherapy for vaginal or cervical cancer.
- Group 1: Ancillary-Correlative (biomarkers in cervical cancer)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many health facilities are participating in this clinical investigation?
"Patients in this trial are being recruited from Grant Medical Center (Columbus, Ohio), Truman Medical Centers (Kansas City, Missouri) and Grady Memorial Hospital (Delaware, Oklahoma). Additionally there are 70 other locations participating."
Is this experiment actively seeking volunteers?
"Clinicaltrials.gov states that this research project is no longer actively looking for participants due to being first posted on February 9th, 2009 and last updated October 27th 2022. However, there are currently 205 other studies in need of patient volunteers."
Has this treatment been granted authorization from the FDA?
"The safety of this treatment has been approximated to be a 1, as it is currently at the initial stage of testing and there is little evidence that suggests its efficacy or security."
Who else is applying?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger